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LESSONS FROM PRACTICE
DEATH FROM AMPHETAMINE USE is a well recognised
occurrence, with most reported fatalities involving the use of
3,4-methylenedioxymethamphetamine (MDMA, or
“ecstasy”). In 1998, a series of six cases of death due to an
unusual amphetamine drug, paramethoxyamphetamine
(PMA), was reported in South Australia.1 The only other
comparable report of deaths due to PMA was that of nine
deaths in Ontario, Canada, in the early 1970s.2 In 1998, our
group warned that, although PMA substitution for MDMA
appeared at the time to be a local Australian problem, there
was a possibility that the manufacture and sale of PMA
could occur in other countries. Unfortunately, this predic-
tion has been proved accurate, with recent reports of PMA-
related deaths in the United States, Europe and Canada.3-5
Initially, it was assumed that PMA was created as a
contaminant during the synthesis of MDMA and was being
disguised and substituted for MDMA by local dealers
attempting to offload the drug.1,6,7 However, this is now
considered unlikely, as the chemical precursors of PMA and
MDMA are different,3,4 and information received concern-
ing Case 3 (described here) suggests that capsules contain-
ing only PMA are being marketed specifically to augment
the effects of MDMA. This is an extremely dangerous
development, as it is well recognised that PMA has a much
greater propensity to produce adverse effects than other
ring-derivative amphetamines.6
Death in each of the cases described here was due to PMA
toxicity with hyperthermia. PMA levels of higher than 0.3
mg/L and MDMA levels higher than 0.6 mg/L have been
found in cases where deaths were attributed to these drugs.1
Roger W Byard,* Nicholas G Rodgers,† Ross A James,‡
Chris Kostakis,§ Andrew M Camilleri§
*Specialist Forensic Pathologist, †Pathology Registrar
‡Chief Forensic Pathologist, §Forensic Scientist
Forensic Science Centre, Adelaide, SA
byard.roger@saugov.sa.gov.au
1. Byard RW, Gilbert J, James R, Lokan RJ. Amphetamine derivative fatalities in
South Australia — is “ecstasy” the culprit? Am J Forensic Med Pathol 1998; 19:
261-265.
2. Cimbura G. PMA deaths in Ontario. CMAJ 1974; 110: 1263-1267.
3. Kraner JC, McCoy DJ, Evans MA, et al. Fatalities caused by the MDMA-related
drug paramethoxyamphetamine (PMA). J Anal Toxicol 2001; 24: 645-648.
4. The hallucinogen PMA: dancing with death. Drug intelligence brief. US
Department of Justice, Drug Enforcement Administration Intelligence Section,
October 2000.
5. Martin TL. Three cases of fatal paramethoxyamphetamine overdose. J Anal
Toxicol 2001; 24: 649-651.
6. Ling LH, Marchant C, Buckley NA, et al. Poisoning with the recreational drug
paramethoxyamphetamine (“death”). Med J Aust 2001; 7: 453-455.
7. White JM, Bochner F, Irvine RJ. The agony of “ecstasy”. Med J Aust 1997; 166:
117-118.
 (Received 17 Oct 2001, accepted 20 Feb 2002) ❏
Death and paramethoxyamphetamine — an evolving problem
Case reports
Lessons from practice
■ Amphetamine ingestion is now not only occurring at dance clubs, 
but also in the home.
■ Paramethoxyamphetamine (PMA), which has much more serious 
adverse effects than other ring-derivative amphetamines, 
continues to be sold in South Australia.
■ PMA is now being marketed and supplied independently as a 
follow-on drug to methylenedioxymethamphetamine (“ecstasy”).
LESSONS FROM PRACTICE
CASE 1: A 22-year-old man complained that he was “burning up” and 
collapsed after ingesting drugs at a friend’s house. He died soon 
afterwards at a local hospital, despite attempts at resuscitation. 
His core temperature was 42oC. At autopsy there was evidence of 
coagulopathy, with scattered bruises, intra-alveolar haemorrhage, 
and haemorrhagic pleural effusions, ascites and stomach contents. 
Toxicological blood analysis revealed  lethal level of PMA 
(1.3 mg/L), together with 0.02 mg/L of MDMA and 0.21 mg/L of 
methylamphetamine. No alcohol was detected in the blood.
CASE 2: An 18-year-old man died at his home after ingesting a 
number of “ecstasy” tablets over five hours, both at a dance club and 
at home. Two hours after death the core temperature of the body was 
39oC. Autopsy revealed focal pericardial haemorrhage, pulmonary 
congestion and renal tubular necrosis. Toxicological blood analysis 
showed a lethal level of PMA (1.7 mg/L), with 0.1 mg/L of MDMA 
and 0.06 mg/L of methylamphetamine. No alcohol was detected 
in the blood.
CASE 3: A 19-year-old man died in hospital 40 hours after being 
brought to the emergency department in respiratory arrest with a 
body core temperature of 41.6C. He had taken “two or three 
capsules” of street drugs of an uncertain nature, both at a “rave” 
party and then at a friend’s home the following day. According to 
witnesses, he had been advised to take PMA for an enhanced effect 
after taking MDMA. Laboratory investigations revealed evidence 
of rhabdomyolysis, with a serum myoglobin level of 328 960 g/L 
(normal level, <150 g/L), disseminated intravascular coagulation and 
marked hyperkalaemia (7.7 mmol/L; normal range, 3.5–5.0 mmol/L).
At autopsy there was evidence of coagulopathy, with epicardial 
petechiae, pulmonary haemorrhage, haemorrhagic gastric and 
intestinal contents, and haemorrhagic serous cavity effusions. There 
was also oedema and necrosis of skeletal muscle and renal tubular 
necrosis. Toxicological blood analysis revealed a lethal level of PMA 
(0.98 mg/L), with 0.32 mg/L of MDMA. No alcohol was detected in 
the blood. Analysis of capsules found with the patient revealed PMA 
with no other amphetamine derivatives.
